Anteris Technologies Global Corp. appointed Brent Moen as its new Chief Financial Officer, effective September 11, 2026. Mr. Moen brings over 25 years of financial leadership experience, including prior CFO roles at LifeLens Technologies, Tactile Systems Technology, and Entellus Medical. His employment agreement includes an annual base salary of $475,000, a target bonus opportunity of up to 50% of base salary, and a long-term incentive award with a target value of $500,000 in nonqualified stock options vesting over three years. Concurrently, outgoing CFO Matthew McDonnell will transition to the role of Head of Australia on September 11, 2026, while retaining his current compensation and benefits. Anteris Technologies Global Corp. operates in the medical technology industry, focusing on developing and commercializing minimally invasive treatments for chronic pain.

Anteris Technologies Global Corp. obtained a court order from the Federal Court of Australia on August 3, 2026, to rectify an administrative oversight regarding the late lodgement of a cleansing notice for 44,068 CHESS Depositary Interests issued on July 10, 2026. The court extended the disclosure period and declared that sales of these interests were not invalid due to the filing delay, relieving sellers from civil liability. Anteris requested that the trading halt in its securities be lifted by the ASX effective August 4, 2026. This matter involves a minor compliance issue rather than operational or financial performance changes. The company operates in the biotechnology industry and develops medical devices for treating obstructive sleep apnea.